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Abstract
Deep learning (DL) methods have in recent years yielded impressive results in medical imaging,
with the potential to function as clinical aid to radiologists. However, DL models in medical
imaging are often trained on public research cohorts with images acquired with a single scanner
or with strict protocol harmonization, which is not representative of a clinical setting. The aim of
this study was to investigate how well a DL model performs in unseen clinical data sets—collected
with different scanners, protocols and disease populations—and whether more heterogeneous
training data improves generalization. In total, 3117 MRI scans of brains from multiple dementia
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1 INTRODUCTION
research cohorts and memory clinics, that had been visually rated by a neuroradiologist according
to Scheltens’ scale of medial temporal atrophy (MTA), were included in this study. By training
multiple versions of a convolutional neural network on different subsets of this data to predict
MTA ratings, we assessed the impact of including images from a wider distribution during
training had on performance in external memory clinic data. Our results showed that our
model generalized well to data sets acquired with similar protocols as the training data, but
substantially worse in clinical cohorts with visibly different tissue contrasts in the images. This
implies that future DL studies investigating performance in out-of-distribution (OOD) MRI data
need to assess multiple external cohorts for reliable results. Further, by including data from a
wider range of scanners and protocols the performance improved in OOD data, which suggests
that more heterogeneous training data makes the model generalize better. To conclude, this is
the most comprehensive study to date investigating the domain shift in deep learning on MRI
data, and we advocate rigorous evaluation of DL models on clinical data prior to being certified
for deployment.
Keywords: Neuroimaging, Deep learning, MRI, Domain shift, Clinical application
1. Introduction
The use of deep learning (DL) models in neuroimaging has increased rapidly in the last
few years, often showing superior diagnostic abilities compared to traditional imaging softwares
(see [1, 2] for reviews). This makes DL models promising to use as diagnostic aid to clinicians.
However, for a software to function in a clinical setting it should work on images acquired from
different scanners, protocol parameters, and of varying image quality—a scenario reflective of
most clinical settings today. Fig. 1 shows illustrative examples of the variability in images from
some different centers included in this study.
adni innomed memclin edlb_c1 edlb_c2
adni_2 innomed_2 memclin_2 edlb_c1_2 edlb_c2_2
ADNI AddNeuroMed MemClin E-DLBC1 E-DLBC2
MTA 0 MTA 1 MTA 2 MTA 3 MTA 4
Figure 1: Two randomly selected images from five different cohorts in the study to illustrate image intensity
variability between cohorts, and examples of Scheltens’ scale of medial temporal atrophy (MTA) rated by a
radiologist. The red boxes show the region of interest for the MTA scale with a progressive worsening in the
hippocampus and surrounding regions. The images are normalized to have zero mean and unit variance, with
the same intensity color scale for all images. The jet color map on the right-hand part of the images is used to
visibly highlight intensity differences between centers.
Training a DL model on magnetic resonance imaging (MRI) scans requires a large dataset to
obtain good performance. However, (labeled) clinical data is generally difficult (and expensive)
to acquire due to strict privacy regulations on medical data. Most researchers are therefore
constrained to rely on publicly available neuroimaging datasets, which are typically research
cohorts that differ from a clinical setting in several ways: 1) Images are acquired from the
same scanner and protocol, or protocols have been harmonized across machines. This is done
to reduce image variability and confounding effects, which are problematic also for traditional
neuroimaging softwares such as FSL, FreeSurfer and SPM [3]. 2) Research cohorts often have
strict inclusion and exclusion criteria for the individuals enrolled in order to study a particular
effect of interest. For instance, to study the progression of patients suffering from Alzheimer’s
Disease (AD) it may be necessary to exclude comorbidities, such as cerebrovascular pathology
or history traumatic brain injury, in order to reduce heterogeneity not relevant to the research
question. This is the case of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort—
the most extensive public neuroimaging data set in AD and used for training and evaluation
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in multiple DL studies on AD [1]. However, since comorbidities are frequent alongside AD the
ADNI cohort is hardly reflective of the heterogeneous AD profiles of patients in the clinics [4, 5].
Thus, training a DL model on data from a research cohort may perform worse in a clinical setting
due to difficulties generalizing to new scanners/protocols (point 1) and/or more heterogeneous
population (point 2). Investigating the performance in out-of-distribution data (OOD data, i.e.
images acquired with different scanners/protocols than the ones included in the training set) is
an important step in order to investigate clinical applicability of DL models and understanding
the challenges that can arise when deploying.
Some previous studies have investigated the clinical applicability of machine learning mod-
els, or domain-shift (training a model on data from one domain and applying it in data from
another). A recent paper by De Fauw et al. (2018) trained and applied a deep learning model
on a clinical dataset of 3D optical coherence tomography scans, which managed to predict re-
ferral decisions with similar performance as experts [6]. However, when applied to images from
a new scanning device the performance was poor. Since they used a two-stage model architec-
ture, where the first part segmented the image into different tissue types (making subsequent
analysis scanner independent), it was sufficient to retrain only the segmentation network with
a (much smaller) data set from the new device. Klo¨ppel and colleagues (2015) investigated the
performance of a trained SVM-classifier to diagnose dementia in a clinical data set of a more het-
erogeneous population [7]. Their models were also fed tissue-segmentation maps, preprocessed
using SPM, and found a drop in performance compared to the ”clean” training set, as well as
lower performance than previous studies had reported (typically cross-validation performance).
Zech et al. (2018) explicitly investigated how a convolutional neural network (CNN) trained
for pneumonia screening on chest X-rays generalized to new cohorts. They found significantly
lower performance in OOD cohorts. Further, they demonstrated that a CNN could accurately
classify which hospital an image was acquired at and thus potentially leverage this information
to adjust the prediction method due to different disease prevalences in the cohorts [8]. Some
recent studies have investigated MRI segmentation performance across centers and again found
drops in performance [9, 10, 11]. These analyses were made on a small number of images, as
segmented data is typically expensive and time-consuming to label. In contrast to segmented
data, visual ratings of atrophy, which still serve as the main tools to quantify neurodegeneration
in memory clinics, offer a faster method to annotate brain images that make it feasible to label
large datasets (>1000 images) from multiple clinics. Our group recently proposed AVRA (Auto-
matic Visual Ratings of Atrophy), a DL model based on convolutional neural networks (CNN)
[12]. AVRA inputs an unprocessed T1-weighted MRI image and predicts the ratings of Scheltens’
Medial Temporal Atrophy (MTA) scale, commonly used clinically to diagnose dementia [13] (see
Fig. 1 for examples of the MTA scale).
The aim of this study is to systematically investigate the performance of a CNN based
model (AVRA) in OOD data from clinical neuroimaging cohorts. We study the impact more
heterogeneous training data has on generalization to OOD data by training and evaluating AVRA
on images from different combinations of cohorts. Two of these cohorts are research oriented:
similar to each other in terms of disease population (AD) and protocol harmonization. The
other two datasets consist of clinical data from multiple European sites including individuals
of different and mixed types of dementia, not just AD. Additionally, we assess the inter- and
intra-scanner variability of AVRA in a systematic test-retest set. To our knowledge this is the
largest and most comprehensive study on the generalization of DL models in neuroimaging and
MRI data.
2. Material and methods
2.1. MRI data and protocols
The 3117 images analyzed in this study came from five different cohorts described in Table
1, where we also list the reasons for including these datasets in the current study. Full lists of
scanners and scanning protocols are provided as Supplementary Data. TheHiveDB was used for
data management in this study [14].
Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neu-
roimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003
as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The pri-
mary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron
3
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Table 1: An overview of how the cohorts used for training and/or evaluation differ from each other, and the
purpose of including them in the present study. The E-DLB cohort (denoted as E-DLBall, referring to all images
in the cohort) was stratified into different subsets in order to isolate specific features of interest. Ntrain/Ntest
refers to the number of labeled images used during training/evaluation, where some cohorts were split into training
and test set. Abbreviations: Deep Learning (DL); Out-of-distribution (OOD) data; Alzheimer’s disease (AD);
Healthy controls (HC); Frontotemporal lobe dementia (FTLD); Dementia with Lewy Bodies (DLB); Parkinson’s
disease with dementia (PDD).
Cohort Scanners/Protocols Disease population Purpose of inclusion
ADNI
Ntrain=1568
Ntest=398
Multiple scanners and
sites, but strictly har-
monized with phan-
tom. Both 1.5T and
3T.
AD spectrum and HC.
Common cohort to train and
evaluate DL models in, which
we hypothesize should not
generalize well.
AddNeuroMed
N=122
Harmonized, designed
to be compatible with
ADNI.
AD patients only.
Assess AVRA in an exter-
nal research cohort similar to
ADNI.
MemClin
Ntrain=318
Ntest=66
Unharmonized, part
of clinical routine
from a single memory
clinic.
Mainly AD spectrum
and HC, with 37 FTLD
patients.
Large clinical cohort with
similar disease population as
ADNI and AddNeuroMed.
E-DLBall
N=645
Retrospective unhar-
monized data of vary-
ing quality from 12
European sites as part
of their clinical rou-
tine.
Mainly DLB spectrum,
but also HC, AD and
PDD.
To assess performance of
AVRA in a large, realistic
clinical cohort.
E-DLBAD
N=193
Same as E-DLBall
Only individuals with
AD pathology from E-
DLBall.
To isolate effects of scan-
ners/protocols not seen dur-
ing training from disease
population.
E-DLBDLB,PDD
N={266,97}
Same as E-DLBall
Only individuals with
DLB or PDD pathol-
ogy from E-DLBall, re-
spectively.
To assess the impact scan-
ners/protocols and disease
populations not seen during
training have on AVRA per-
formance.
E-DLB25,50%
Ntrain={173,312}
Ntest= 333
Same as E-DLBall
Randomly selected im-
ages with a probability
of 25% (or 50%) from
all centers in E-DLBall.
To assess effect of including
training data from test set
distribution has on AVRA
performance.
E-DLBC1,C2
Ntrain=379
Ntest={101,165}
Both centers have
used a single scanner
(3T) and protocol.
Stratifying images into
three groups: from cen-
ter C1, from C2, and all
images not in C1, C2
from E-DLBall.
”External validation sets”:
how would AVRA perform
if deployed in two external
memory clinics?
Test-Retest
N=72
Three Siemens scan-
ners (two 1.5T, one
3T) with similar pro-
tocols but unharmo-
nized.
Young (38 ± 13 years
old) MS patients and
healthy controls.
Systematic evaluation of the
impact scanner variability
has on AVRA predictions.
emission tomography (PET), other biological markers, and clinical and neuropsychological as-
sessment can be combined to measure the progression of mild cognitive impairment (MCI) and
early Alzheimer’s disease (AD). In brief, the ADNI dataset is a large, public dataset that has
been helped advance the field of AD and neuroimaging. However, the strictly harmonized proto-
cols and strict exclusion criteria make ADNI unrepresentative of a clinical setting. Some subjects
were scanned multiple times (within a month) in both a 1.5T and a 3T scanner in which case
one of the images was selected at random during training for the current study. AddNeuroMed
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is an imaging cohort collected in six sites across Europe with the aim of developing and vali-
dating novel biomarkers for AD [15]. The MRI images were acquired with protocols designed to
be compatible with data from ADNI, and the two cohorts have been successfully combined in
previous studies [16, 17, 18]. AddNeuroMed was an interesting cohort to assess AVRA’s reliabil-
ity in due to having consistent scanning parameters and acquisition methods similar to ADNI.
Thus, this dataset represented a research cohort where we expected our DL model to show good
performance in when trained on ADNI data. A subset of the images (122) of patients diagnosed
with AD had been visually rated for MTA. Exclusion criteria for both these studies included no
histories of head trauma, neurological or psychiatric disorders (apart from AD), organ failure,
or drug/alcohol abuse.
The MemClin data set was used for training also in our previous study detailing AVRA [12].
MemClin consists of images of AD or frontotemporal lobe dementia collected from the memory
clinic at Karolinska Hospital in Huddinge, Sweden. This data set better resembled a clinical
setting with varying scanning parameters and field strengths, while the disease population was
not completely representative of patients in a memory clinic. The only exclusion criteria was
history of traumatic brain injury. Images and ratings have previously been analyzed in [19, 20].
The fourth cohort in this study consists of clinical MRI images from the European consortium
for Dementia with Lewy Bodies (referred to as E-DLB from here on) previously described in [21,
22]. Patients with referrals to memory, movement disorders, psychiatric, geriatric or neurology
clinics that had undergone an MRI were selected from 12 sites in Europe. These individuals were
diagnosed with Dementia with Lewy Bodies (DLB), AD, Parkinson’s Disease with Dementia
(PDD), mild cognitive impairment (MCI, due to AD or DLB), or were normal elderly controls
(NC). The images were acquired as part of the clinical routine, and consequently without protocol
harmonization, and can thus be considered to reflect a clinical setting well. Exclusion criteria
for the E-DLB cohort were having received a recent diagnosis of major somatic illness, history
of psychotic or bipolar disorders, acute delirium, or terminal illness.
We also investigated AVRA’s rating consistency on unprocessed MRI images (i.e. no lesion
filling) of three healthy and nine individuals with Multiple Sclerosis (MS, mean disease duration
7.3± 5.2 years) that were scanned twice with repositioning in three different Siemens scanners
(i.e. six scans in total) in a single day. Six of the patients had relapsing-remitting MS, two
secondary progressive MS, and one primary progressive MS. This data set was collected for a
previous study [3], and we will refer to this small set as the test-retest dataset. These individuals
were not rated for MTA by a radiologist.
2.2. Radiologist ratings
An experienced neuroradiologist (Lena Cavallin, L.C.) visually rated 3117 T1-weighted brain
images (blind to age and sex) according to the established MTA rating scale. These ratings have
been used in previous studies on AD [23] and E-DLB [22] by our group, and the distribution of
ratings are shown in Table 2. These rating scales provide a quantitative measure of atrophy in
specific regions, and while they are often used for dementia diagnosis the rating scales themselves
are independent of diagnosis, age and sex. L.C. has previously demonstrated excellent inter- and
intra-rater agreements in research studies [12].
2.3. Model description
Our group recently proposed a method we call AVRA (Automatic Visual Ratings of Atrophy)
that provides computed scores of three visual rating scales commonly used clinically: Scheltens’
MTA scale (see Fig. 1), Pasquier’s frontal subscale of global cortical atrophy (GCA-F), and
Koedam’s scale of posterior atrophy (PA) [12]. AVRA showed substantial rating-agreement to
an expert neuroradiologist in all three scales on a hold-out test set (N=464) that was drawn from
the same distribution as the training data (N=1886) from two AD cohorts. Since the measures
are independent of diagnosis, sex and age, a DL tool such as AVRA (trained end-to-end and does
its own feature-extraction from the entire brain volume) should work equally well on different
disease populations.
For this experiment we focused only on the MTA scale and used the same network architecture
and hyperparameters as previously described in [12], but with different combinations of cohorts
in the training set. Briefly, AVRA is a Recurrent Convolutional Neural Network (R-CNN)
that inputs an unprocessed MRI volume, which is then processed slice-by-slice by the model. A
5
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Table 2: Distribution of MTA ratings from a neuroradiologist in the different cohorts, together with sex (female
percentage) and age demographics. The lines in bold refers to the statistics of the whole cohort, whereas the rows
not in boldface text are the subsets used for during training. N is the total number of rated images, and since
both left and right hemispheres were rated there were 2N ratings. MTA distribution shows the percentage of
each radiologist rating per (sub-)cohort. A small linespace are added between some E-DLB subsets to illustrate
the grouping of the subsets where no overlap between training and test sets occur.
Cohort N MTA distribution, (%) Females Age
Subset 0 1 2 3 4 (%) (mean ± std)
ADNIall 1966 11 40 29 14 6 41 76.9 ± 6.6
ADNItrain 1568 11 40 29 14 6 41 77.0 ± 6.6
ADNItest 398 12 39 28 16 5 43 76.6 ± 6.9
AddNeuroMed 122 2 21 41 23 13 66 75.7 ± 6.1
MemClinall 384 3 35 39 18 6 57 68.0 ± 8.2
MemClintrain 318 3 34 40 17 6 56 68.0 ± 8.2
MemClintest 66 4 39 33 21 4 61 68.3 ± 8.2
E-DLBall 645 14 41 29 12 4 44 73.7 ± 8.0
E-DLBtrain25 149 15 40 28 12 4 43 74.2 ± 8.1
E-DLBtrain50 324 15 41 29 11 3 45 74.0 ± 8.1
E-DLBtest50 321 12 42 29 12 5 43 73.4 ± 8.0
E-DLBtrainC1,C2 379 11 42 30 15 3 51 73.7 ± 7.5
E-DLBC1 101 16 40 29 11 4 23 75.9 ± 6.5
E-DLBC2 165 19 41 28 6 5 41 72.3 ± 9.5
E-DLBAD 193 4 30 38 20 7 55 75.7 ± 7.7
E-DLBDLB 266 14 43 28 11 4 44 73.6 ± 8.2
E-DLBPDD 97 19 46 27 7 1 15 71.8 ± 7.0
residual attention network [24] is used to extract features from each slice, and these are forwarded
to a Long-Short Term Memory (LSTM) network [25]. The LSTM modules remember relevant
information provided from each slice and use it to predict the atrophy score the radiologist
would give. This prediction is continuous, but when studying the inter-rater agreement with the
radiologist, expressed in kappa statistics or accuracy, we round AVRA’s output to the nearest
integer.
A trained version of AVRA is publicly available targeted towards neuroimaging researchers
at https://github.com/gsmartensson/avra_public.
2.4. Training procedure
To systematically investigate the performance in new data distributions we trained versions
of AVRA on data where we kept the number of subjects fixed to the maximum size of the ADNI
training data (N = 1568), since more training data generally leads to better performance and
could bias the results. ADNI was the largest dataset with ratings available to us, and needed
to be part of all training sets in order for the number of images to be large enough for training.
When combining data from an additional cohort, we replaced a subject in ADNI with one from
the new cohort that had the same ratings from the radiologist. This way, both the size and
the distribution of the training data were kept constant. Each training set was divided into five
cross-validation sets (to replicate the procedure in [12]) and these five trained models were used
as an ensemble classifier.
Each of the cohorts have different characteristics, as outlined in Table 1. Since the E-DLB
cohort was highly diverse in terms of scanners and disease population, we stratified it into
different partitions (some with overlap, but no training/test set pairs shared any images) in
order to isolate specific features. To investigate the performance drop due to OOD test data, we
randomly assigned each subject into E-DLBtrain25% , E-DLB
train
50% and E-DLB
test
50%, where the numbers
refer to the percentage of subject from the whole cohort and with no overlap between train and
test. This setup aims to simulate realistic ways of introducing a DL model into a new clinic:
1) as is (i.e. no additional labeled data from the new clinic), 2) retraining, or finetuning, the
existing model with some additional labeled data from the same clinics (E-DLB25%), 3) same as
2) but with twice as much additional data (E-DLBtrain50% ).
To assess the impact of disease population we sampled individuals on the AD spectrum (E-
DLBAD), DLB spectrum (E-DLBDLB), or with PDD (E-DLBPDD) into three subsets. Since the
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main bulk of training images comes from ADNI—an AD cohort—it is of interest to see if the
models overfit to AD atrophy patterns and are influenced by neighboring regions in the medial
temporal lobe not part of the MTA scale.
To study if AVRA’s generalizability improved when widening the training data distribu-
tion we also computed the performance on data from two clinics that we refer to as E-DLBC1
and E-DLBC2. A single 3T scanner and protocol was used at each site for scanning, yet with
visibly different image intensities (see image examples in Fig. 1). We view these centers as
”external validation sets” to estimate the performance we may expect if implementing AVRA
in a new memory clinic (although single-scanner usage and study populations may not perfectly
represent a memory clinic sample). We included data from all other centers to our training
set (E-DLBtrainC1,C2) to study if more heterogeneous training data improves generalization to new
protocols.
2.5. Evaluation metrics
We assess the performance of AVRA using Cohen’s linearly weighted kappa κw, which is the
most common metric to assess inter- and intra-rater agreement for visual ratings in the literature.
It ranges from [-1,1] where κw ∈ [0.2,0.4) is generally considered fair, κw ∈ [0.4,0.6) moderate, κw
∈ [0.6,0.8) substantial and κw ∈ [0.8,1] almost perfect [26]. As opposed to accuracy, κw takes the
rating distributions of the two sets into account, which is particularly useful when the number
of ratings in each class are imbalanced. As comparison, AVRA achieved inter-rater agreements
of κw = 0.72 - 0.74 (left and right MTA, respectively) to an expert radiologist on a test set from
the same data distribution as the training data in [12], similar to reported inter-rater agreements
between two radiologists. Since using κw required rounding AVRA’s continuous predictions to
the nearest integer, mean squared error (MSE) was also reported. Accuracies are included as
Supplementary Data.
3. Results
The rating agreements between AVRA and the neuroradiologist are summarized in Table
3. When only training on the research cohort ADNI we saw a general drop in performance in
clinical cohorts compared to the test set of ADNI—particularly in the E-DLBC1 set. Adding
data from the similar cohort AddNeuroMed helped little in improving generalization, whereas the
inclusion of clinical MemClin had a positive impact on performance. The overall impression was
that including data from clinical cohorts in the training set improved the rating agreements and
accuracies in the clinical test sets, although not consistently. Surprisingly, the rating agreement
was greater in the sub-cohorts E-DLBDLB and E-DLBPDD than in E-DLBAD when only training
on images from AD cohorts.
In Fig. 2 we focus on the centers E-DLBC1 and E-DLBC2, where AVRA’s performance
metrics were particularly low (C1) or close to within-distribution test set performances (C2)
when trained on research data. We compared the predictions made by the ensemble models
trained only on ADNI (x-axis) to when trained on data from ADNI and clinical images from
the MemClin and E-DLBtrainC1,C2 cohorts. Thus, no images from these centers had been part in
either of the training sets, but the latter included clinical images acquired from a wider range of
protocols. We observed systematic differences in the predictions between the two models, most
notably in the C1 cohort. Note the intensity differences in tissue types between images from
ADNI, C1 and C2 in Fig. 1.
AVRA’s MTA ratings on the test-retest cohort are plotted in Fig. 3 for the models trained
on the least and most heterogeneous data. We observed small intra-subject rating variability
for most subjects, within the same model. It was mainly the predictions of the two images
acquired with the Siemens Trio 3T that stood out. While the direction of the rating prediction
differences were not consistent across subjects, it suggests that AVRA may systematically rate
images acquired from some protocols/scanners differently. Comparing the two versions we see
that the model trained only on ADNI systematically rates images lower than when trained also
on clinical data—same as in Fig. 2. Further, it should be noted that these participants were
younger than in any of the training cohorts and—for the patients suffering from MS—from a
different disease population.
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Table 3: Rating agreement between AVRA and a neuroradiologist expressed in Cohen’s κw and mean squared
error (MSE) for various test sets when trained on different combinations of training cohorts. The number of
training subjects were kept constant to N = 1568 together with a fixed label distribution. A X symbol in a column
denotes that the cohort of that row was part of the training set. E.g. the first column shows the rating agreement
and MSE for different test sets when trained only on ADNI, the second when trained on ADNI+AddNeuroMed,
etc. If there was any overlap between images in a training and test set combination no agreement was computed
(listed as ’—’ in the table). The greatest agreement values for each test set are in bold.
Cohort Cohorts incl. in training
ADNItrain X X X X X X X X X X X X
AddNeuroMed X X X X
MemClintrain X X X X
E-DLBtrainC1,C2 X X X X
E-DLBtrain25 X
E-DLBtrain50 X X
E-DLBAD X
E-DLBDLB X
Cohen’s κw
ADNItest 0.70 0.71 0.70 0.71 0.69 0.71 0.70 0.69 0.68 0.70 0.68 0.69
AddNeuroMed 0.72 — 0.65 0.65 0.64 — — 0.68 0.66 — 0.70 0.68
MemClin 0.65 0.66 — 0.67 — 0.68 — 0.65 0.63 — 0.69 0.71
MemClintest 0.67 0.68 0.76 0.73 0.78 0.71 0.77 0.69 0.63 0.73 0.66 0.79
E-DLBall 0.61 0.59 0.64 — — — — — — — — —
E-DLBtest50 0.62 0.59 0.63 — — — — 0.63 0.67 0.68 — —
E-DLBAD 0.51 0.54 0.59 — — — — — — — — 0.65
E-DLBDLB 0.63 0.59 0.65 — — — — — — — 0.63 —
E-DLBPDD 0.69 0.60 0.62 — — — — — — — 0.65 0.66
E-DLBC1 0.34 0.33 0.51 0.38 0.55 0.55 0.58 — — — — —
E-DLBC2 0.67 0.60 0.68 0.66 0.68 0.67 0.64 — — — — —
Mean squared error
ADNItest 0.26 0.25 0.25 0.25 0.26 0.25 0.25 0.27 0.27 0.27 0.26 0.26
AddNeuroMed 0.22 — 0.24 0.24 0.25 — — 0.22 0.24 — 0.23 0.23
MemClin 0.29 0.26 — 0.25 — 0.23 — 0.26 0.26 — 0.24 0.23
MemClintest 0.28 0.23 0.19 0.21 0.18 0.21 0.19 0.24 0.24 0.21 0.25 0.18
E-DLBall 0.35 0.35 0.29 — — — — — — — — —
E-DLBtest50 0.34 0.33 0.29 — — — — 0.28 0.27 0.27 — —
E-DLBAD 0.43 0.41 0.31 — — — — — — — — 0.27
E-DLBDLB 0.35 0.36 0.32 — — — — — — — 0.32 —
E-DLBPDD 0.25 0.25 0.22 — — — — — — — 0.25 0.21
E-DLBC1 0.75 0.71 0.40 0.44 0.38 0.37 0.36 — — — — —
E-DLBC2 0.22 0.25 0.25 0.23 0.22 0.23 0.24 — — — — —
4. Discussion
In this study we systematically showed that the performance of a CNN trained on MRI
images from homogeneous research cohorts generally drops when applied to clinical data. In
one center—where image intensity was visibly different to images from the training data—the
performance of AVRA was lower due to a systematic underestimation. However, by including
images acquired from a wider range of scanners and protocols in the training set we observed an
increase in robustness/reliability of the DL model in unseen OOD data—without a substantial
damage to the within-distribution test set performance. This is the first study on a large MRI
neuroimaging data set labeled by the same expert neuroradiologist (thus no inter-observability
bias) and with fixed training set sizes and label distribution. These results add to the evidence
that rigorous testing of DL applications in medical imaging needs to be performed on external
data before being used in clinics.
From our results in Table 3 we note several interesting findings. First, the level of agreement
is lower in the clinical cohorts MemClin and E-DLBall when only trained on research cohorts
(ADNI with or without AddNeuroMed). This suggests that we can expect a degradation of a
CNN model when applied to MRI images acquired with protocols not seen during training, which
is problematic for scalable deployment in clinics. Similar findings have previously been reported
on segmentation tasks on cross-institutional MRI data [10, 11] and chest x-ray data [27, 28].
While inter-rater agreement levels of κw > 0.6 might be considered acceptable in many clinical
situations for visual ratings (reported κw levels between radiologists are typically between 0.6
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Figure 2: Scatter plot of the AVRA predictions of the images from E-DLBC1 (left) and E-DLBC2 (right),
which respectively showed poor and good agreement using the baseline model trained only on ADNI. Each dot
represents a subject, where the x-coordinate is the prediction when trained only on the ADNI cohort, and the
y-coordinate where images from clinical cohorts were also represented in the training data. The marker symbols
and colors indicate radiologist’s (”ground truth”) ratings. The dotted line show x = y, making it clear that
AVRA’s predictions were systematically lower than if including data from a wider distribution in the training set.
This was very prominent in the E-DLBC1 cohort, but also notable in E-DLBC2.
and 0.8 in previous studies [12]) we see that the agreement in E-DLBC1 is substantially lower
when only trained on data from harmonized research cohorts. Further, the performance drop
observed in E-DLBC1 but not in E-DLBC2 implies that evaluating DL models in data from a
single external center is not sufficient to assess the degree of generalization. In order to deploy
a clinical DL model we believe that it is necessary to report the epistemic uncertainty of a
prediction, i.e. the model’s uncertainty due to not having been previously exposed to a similar
image during training. This would signal that more ”E-DLBC1-like” data needs to included in
the training set for the DL model to show good performance in C1 (sometimes referred to as
active learning). Developing scalable methods to estimate DL model uncertainty—or being able
to detect OOD data—is an active research field but was not explored in the current study and
dataset.
Second, including images of larger variability from clinical cohorts improved performance even
when keeping the training set size and label distribution fixed. Including data from MemClin in
the training set had a positive impact on the E-DLB sets and vice versa. This implies that by
training a supervised DL model on data from a wide range of scanners, protocols, field strengths
and diagnoses/labels it is possible to achieve acceptable performance on new unseen data. The
systematic prediction differences for E-DLBC1 in Fig. 2 illustrates this point well, where training
data from other memory clinics had a large impact on predictions.
Third, we investigated the performance of AVRA in DLB and PDD populations when trained
on images of subjects on the AD spectrum (from healthy controls, to patients with mild cognitive
impairment and AD). Unexpectedly, the agreement was higher in both the DLB and PDD
populations than in the AD population from the E-DLB cohort. These results could potentially
be explained by the differences in rating distributions between the disease populations. PDD
and DLB individuals generally had lower MTA ratings than the AD patients, and from Fig. 2
we see that the model trained only on ADNI tends to rate too low—particularly for higher MTA
values. Thus, this systematic error could affect the AVRA performance in the AD population
more. However, the relatively high agreements of E-DLBDLB and E-DLBPDD show potential that
AVRA has the ability to generalize across disease populations. This finding is likely attributed
to the strength of the clinical visual rating scales—which are disease-unspecific by design—
and demonstrate the power of incorporating domain knowledge when building DL models. A
previous study on applying machine learning models (SVM) on unseen clinical data reported and
discussed difficulties in determining if subjects suffered from mixed pathologies (e.g. both AD
and FTD) or a misdiagnosis [7]. A model trained to discriminate between e.g. AD patients from
healthy controls—both generally defined by strict inclusion and exclusion criteria in research
cohorts—does just that. Applying an ”AD model” like this in a more heterogeneous cohort
with controls, AD and DLB subjects, would thus most probably misdiagnose DLB as AD due
to resembling patterns of atrophy [22].
The test-retest results (Fig. 3) show impressive consistency for each DL model in most
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Figure 3: Boxplot of AVRA ratings of left MTA (left column) and right MTA (right column) for all par-
ticipants in the test-retest dataset. Top row: model trained only on ADNI; Bottom row: model trained on
ADNI+AddNeuroMed+MemClin+E-DLBtrainC1,C2. Each subject was scanned twice with repositioning in three dif-
ferent scanners, and each image’s AVRA rating is plotted in different colors depending on scanner. Individuals
denoted with the prefix HC were healthy controls and MS were patients with Multiple Sclerosis.
predictions. The ratings from the version trained on multiple data sets seems to yield higher
variability for many subjects compared to when only trained on ADNI. Given that this model
showed better generalization in the analyses summarized in Table 3, this is a bit counterintu-
itive. It should be noted however that these differences are small considering being trained on
integer ratings with some degree of intra-rater variability. The explanation for this inter-scanner
variability could partially be due to a minor overfit to scanner and protocol. This is however to
prefer to the ADNI-model where the ratings seems to be systematically too low. Within-scanner
and within-field strength variability was practically non-existent, and it is only the images of the
3T scanner that notably deviates for some patients. This means that we expect AVRA to be
useful for longitudinal studies, where the data is typically collected in a harmonized way. Guo
et al. (2019) analyzed the same dataset using different (non-machine learning) neuroimaging
softwares and reported smaller within- than between-scanner variability [3]. A previous study
investigating the impact choice of scanner and field strength have on the performance of an SVM-
classfier found the largest performance drop when training on 1.5T data and testing on 3T data
and vice versa, while generalizing well to new scanners within the same field strength [29]. The
analyses in [29] were done in the ADNI cohort, with protocols harmonized using a phantom to
reduce scanner and site variability. For computer scientists it would solve many practical issues
if protocols were harmonized across clinics, and that these protocols were used as default. How-
ever, this seems unlikely given the enormous effort of implementing it, the development of new
(improved) sequences, and disrupting habits and workflows of clinicians. Further, the real gain
of machine learning applications would be on CT images—as it is cheaper and more commonly
available—where image quality variation is even greater. Thus, scanner/protocol generalization
remains an important issue that needs solving prior to deploying DL models as clinical aid. Since
labeled data in medicine is often difficult or expensive to acquire semi-supervised approaches may
play a big role in medical machine learning applications as it allows the inclusion of unlabeled
images in the training data. This has been shown to improve generalization on medical OOD
data [9, 10, 30].
The current study has some limitations that we leave as future studies. Foremost, we trained
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and evaluated a single network architecture and we cannot say to what degree the results are
representative of DL models in general. By using the same hyperparameters as in [12] (tuned
to optimize performance on a within-distribution cross-validation set) nothing prevented AVRA
from overfitting to the training protocol. Further, while the kappa metric is the most common
way to quantify reliability of visual ratings, it can be noisy since we need to round the predic-
tion to nearest integer. The MSE metric does not require rounding but is on the other hand
sensitive to outliers. Since AVRA takes unprocessed MRI images as input—just as a radiologist
would—we did not explore the impact of preprocessing or intensity normalization could have on
generalization.
5. Conclusion
In this study we assessed how well a supervised deep learning model (AVRA), trained on
unprocessed MRI brain images to predict Scheltens’ MTA score, generalizes to external clinical
data. More specifically, we trained multiple versions of AVRA on data from different combina-
tions of research and clinical cohorts, while keeping training set size and label distribution fixed.
We found that AVRA trained on homogeneous data from a research cohort generalized well to
cohorts with similar protocols, but worse when applied to clinical data. On images from one
specific memory clinic the performance dropped to an unacceptably low level. Including more
heterogeneous data from a wider range of scanner and protocols during training improved the
performance also in out-of-distribution data. Furthermore, when applying AVRA on images of
patients suffering from other neurological disorders than AD we did not observe a noticeable
decrease in performance. From these findings we advocate that DL models need to be rigorously
tested in OOD data before being deployed in clinics. This is, to our knowledge, the largest and
most comprehensive study to date on the effect of domain-shift in MRI images and deep learning
models.
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APPENDIX A SUPPLEMENTARY DATA
Appendix A. Supplementary data
As supplementary data we provide accuracy results complementary to MSE and Cohen’s κw in Table
A.1. The full list of scanning parameters are found in Tables A.2-A.6.
Table A.1: Accuracy of (rounded) AVRA predictions and a neuroradiologist for different combinations of training
cohorts and test sets. The number of training subjects were kept constant to N = 1568 together with a fixed
training distribution. A X symbol in a column denotes that the cohort of that row was part of the training set.
E.g. the first column shows the rating agreement and mean squared error for different test sets when trained
only on ADNI, the second when trained on ADNI+AddNeuroMed, etc. If there was any overlap between images
in a training and test set combination no agreement was computed (listed as ’—’ in the table). The greatest
agreement values for each test set are in bold.
Cohort Training combination
ADNItrain X X X X X X X X X X X X
AddNeuroMed X X X X
MemClintrain X X X X
E-DLBtrainC1,C2 X X X X
E-DLBtrain25 X
E-DLBtrain50 X X
E-DLBAD X
E-DLBDLB X
Accuracy
ADNItest 0.68 0.70 0.68 0.71 0.68 0.70 0.69 0.67 0.68 0.69 0.66 0.67
AddNeuroMed 0.72 — 0.65 0.65 0.64 — — 0.68 0.66 — 0.69 0.68
MemClin 0.66 0.67 — 0.68 — 0.70 — 0.67 0.65 — 0.70 0.72
MemClintest 0.67 0.70 0.77 0.74 0.79 0.73 0.79 0.71 0.65 0.74 0.65 0.80
E-DLBall 0.63 0.61 0.65 — — — — — — — — —
E-DLBtest50 (321) 0.64 0.61 0.65 — — — — 0.63 0.68 0.69 — —
E-DLBAD 0.56 0.57 0.60 — — — — — — — — 0.65
E-DLBDLB 0.64 0.61 0.66 — — — — — — — 0.65 —
E-DLBPDD 0.75 0.69 0.69 — — — — — — — 0.71 0.73
E-DLBC1 0.49 0.40 0.58 0.50 0.57 0.59 0.60 — — — — —
E-DLBC2 0.65 0.61 0.67 0.65 0.67 0.67 0.63 — — — — —
Cohort description:
MemClin: Images from the Memory Clinic at Karolinska Hospital.
E-DLBall: All images in the E-DLB cohort.
E-DLBAD,DLB: Only individuals with AD (or DLB) pathology in the E-DLB cohort.
E-DLB25,50: 25% (or 50%) of randomly sampled images from the E-DLB cohort.
E-DLBtrainC1,C2: All images from E-DLB except from centers C1 (or C2) from E-DLB.
E-DLBtestC1,C2: Only images from centers C1 (or C2) from E-DLB.
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Table A.2: Detailed MRI protocols and scanners from the ADNI cohort, where each row represent an individual
scanner. Abbreviations: Echo time (TE); Repetition time (TR); Inversion recovery time (IT); Slice thickness
(ST); Resolution in x-y-plane (x-y).
Scanner N FS (T) TE (ms) TR (ms) IT (ms) x-y (mm) ST (mm)
GE Genesis signa 114 1.5 4.10 10.20 1000 0.94 1.20
GE Genesis signa 16 1.5 4.08 - 4.10 10.20 1000 0.94 - 1.02 1.20
GE Genesis signa 18 1.5 4.09 10.40 1000 0.94 1.20
GE Genesis signa 39 3 3.05 7.50 900 1.02 1.20
GE Genesis signa 4 1.5 4.09 10.20 1000 0.94 1.20
GE Genesis signa 48 1.5 4.08 - 4.10 10.20 1000 0.94 - 1.09 1.20
GE Genesis signa 89 1.5 4.09 10.40 1000 0.94 1.20
GE Signa excite 10 3.0 2.84 - 2.85 6.61 - 6.63 900 1.02 1.20
GE Signa excite 107 1.5 3.92 - 4.05 8.90 - 9.20 1000 0.94 - 1.02 1.20
GE Signa excite 14 1.5 3.80 - 3.90 8.59 - 8.81 1000 0.94 1.20
GE Signa excite 155 1.5 3.80 - 3.92 8.59 - 8.99 1000 0.94 - 0.98 1.20
GE Signa excite 158 1.5 3.92 - 4.05 8.92 - 9.20 1000 0.94 1.20
GE Signa excite 17 1.5 3.96 9.12 1000 0.94 1.20
GE Signa excite 2 1.5 3.96 9.12 1000 0.94 1.20
GE Signa excite 21 1.5 3.80 8.59 1000 0.94 1.20
GE Signa excite 24 3.0 2.84 - 2.85 6.62 - 6.63 900 1.02 1.20
GE Signa excite 30 1.5 3.92 - 4.06 8.92 - 9.22 1000 0.94 1.20
GE Signa excite 34 3.0 2.84 - 2.99 6.61 - 7.04 900 1.02 1.20
GE Signa excite 39 1.5 3.80 - 3.91 8.60 - 8.84 1000 0.94 1.20
GE Signa excite 45 1.5 3.96 9.12 1000 0.94 1.20
GE Signa excite 46 1.5 3.80 - 3.90 8.59 - 8.81 1000 0.94 1.20
GE Signa excite 51 1.5 3.92 - 4.05 8.92 - 9.20 1000 0.94 1.20
GE Signa excite 52 1.5 3.92 - 3.94 8.92 - 8.94 1000 0.94 1.20
GE Signa excite 56 1.5 3.78 - 3.98 8.56 - 9.12 1000 0.94 - 1.02 1.20
GE Signa excite 60 1.5 3.79 - 3.91 8.58 - 8.84 1000 0.94 - 1.02 1.20
GE Signa excite 8 3.0 2.86 - 3.01 6.64 - 6.96 900 1.02 1.20
GE Signa excite 84 1.5 3.92 - 3.96 8.92 - 9.12 1000 0.94 1.20
GE Signa excite 88 1.5 3.80 - 3.90 8.59 - 8.81 1000 0.94 1.20
GE Signa excite 9 3.0 2.84 - 2.99 6.62 - 6.91 900 1.02 1.20
GE Signa excite 93 1.5 3.96 9.12 1000 0.94 1.20
GE Signa excite 95 1.5 3.78 - 3.91 8.57 - 8.84 1000 0.94 1.20
GE Signa hdx 10 3.0 2.84 - 2.85 6.61 - 6.63 900 1.02 1.20
GE Signa hdx 106 1.5 3.80 8.59 1000 0.94 1.20
GE Signa hdx 149 1.5 3.79 - 4.96 8.58 - 11.05 1000 - 1044 0.94 - 1.09 1.20
GE Signa hdx 16 1.5 3.80 - 3.90 8.59 - 8.81 1000 0.94 1.20
GE Signa hdx 20 1.5 3.80 - 3.90 8.59 - 8.81 1000 0.94 1.20
GE Signa hdx 24 1.5 3.92 8.92 1000 0.94 1.20
GE Signa hdx 25 1.5 4.04 9.18 1000 0.94 1.20
GE Signa hdx 50 1.5 3.80 8.59 1000 0.94 1.20
GE Signa hdx 6 1.5 3.80 8.59 1000 0.94 1.20
GE Signa hdx 92 1.5 3.80 - 3.92 8.59 - 8.99 1000 0.94 1.20
GE Signa hdx 92 1.5 3.97 - 4.05 9 - 9.20 1000 0.94 1.20
GE Signa hdxt 2 1.5 3.80 8.60 1000 0.94 1.20
GE Signa hdxt 6 3.0 2.84 - 2.85 6.61 - 6.63 900 1.02 1.20
Philips Achieva 12 3.0 3.05 - 3.17 6.39 - 6.81 1000 1.00 1.20
Philips Achieva 24 3.0 3.25 6.85 1000 1.00 1.20
Philips Achieva 35 3.0 3.13 - 3.25 6.78 - 6.85 1000 1.00 1.20
Philips Achieva 65 1.5 4 - 4.01 8.62 1000 0.90 - 0.98 1.20
Philips Intera 10 3.0 3.16 6.80 0 - 1000 1.00 1.20
Philips Intera 17 3.0 3.16 - 3.18 6.80 - 6.92 0 - 1000 1.00 1.20
Philips Intera 2 3.0 3.16 6.80 0 1.00 1.20
Philips Intera 26 3.0 3.13 - 3.25 6.76 - 6.84 1000 1.00 1.20
Philips Intera 34 1.5 3.99 - 4.01 8.58 - 8.62 0 - 1000 0.94 - 0.98 1.20
Philips Intera 38 1.5 4 8.62 0 - 1000 0.94 1.20
Philips Intera 4 1.5 4 8.62 1000 0.94 1.20
Philips Intera 4 3.0 3.16 6.80 - 6.81 1000 1.00 1.20
Philips Intera 40 1.5 3.98 - 4.01 8.51 - 8.62 1000 0.94 1.20
Philips Intera 48 3.0 3.16 6.80 - 6.81 1000 1.00 1.20
Philips Intera 54 1.5 3.99 - 4.01 8.51 - 8.63 1000 0.94 - 0.98 1.20
Philips Intera 6 1.5 4 - 4.01 8.61 1000 0.94 1.20
Philips Intera 6 3.0 3.13 - 3.25 6.76 - 6.84 1000 1.00 1.20
Philips Intera 61 1.5 4 8.61 - 8.62 1000 0.94 1.20
Philips Intera 66 1.5 4 8.59 - 8.61 1000 0.94 1.20
Philips Intera achieva 4 1.5 3.98 8.55 1000 0.94 1.20
Siemens Allegra 12 2.9 2.91 2300 900 1.00 1.20
Siemens Allegra 54 2.9 2.91 2300 900 1.00 1.20
Siemens Allegra 72 2.9 2.91 2300 900 1.00 1.20
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Siemens Avanto 109 1.5 3.50 2400 1000 1.25 1.20
Siemens Avanto 30 1.5 3.50 2400 1000 1.25 1.20
Siemens Avanto 30 1.5 3.52 - 3.54 2400 1000 1.25 - 1.30 1.20
Siemens Avanto 4 1.5 3.50 2400 1000 1.25 1.20
Siemens Avanto 44 1.5 3.50 2400 1000 1.25 1.20
Siemens Avanto 52 1.5 3.52 - 3.54 2400 1000 1.25 - 1.30 1.20
Siemens Avanto 63 1.5 3.50 2400 1000 1.25 1.20
Siemens Espree 8 1.5 3.59 2400 1000 1.25 1.20
Siemens Sonata 116 1.5 3.54 2400 1000 1.25 1.20
Siemens Sonata 117 1.5 3.54 2400 1000 1.25 1.20
Siemens Sonata 63 1.5 3.54 3000 1000 1.25 1.20
Siemens Sonata 72 1.5 3.54 3000 1000 1.25 1.20
Siemens Sonata 77 1.5 3.54 - 3.55 3000 1000 1.25 1.20
Siemens Sonatavision 2 1.5 3.57 3000 1000 1.25 1.20
Siemens Sonatavision 30 1.5 3.54 2400 1000 1.25 1.20
Siemens Symphony 100 1.5 3.61 3000 1000 1.25 1.20
Siemens Symphony 104 1.5 3.61 - 3.67 3000 1000 1.25 1.20
Siemens Symphony 2 1.5 3.61 3000 1000 1.25 1.20
Siemens Symphony 20 1.5 3.61 3000 1000 1.25 1.20
Siemens Symphony 29 1.5 3.61 3000 1000 1.25 1.20
Siemens Symphony 30 1.5 3.67 - 3.71 3000 1000 1.25 - 1.35 1.20
Siemens Symphony 58 1.5 3.61 - 3.79 3000 1000 1.25 - 1.35 1.20
Siemens Symphony 81 1.5 2.88 - 3.65 3000 1000 1.25 1.20
Siemens Symphony 92 1.5 3.87 3000 1000 1.25 1.20
Siemens Symphony 97 1.5 3.59 - 3.63 3000 1000 1.25 - 1.30 1.20
Siemens Symphonytim 110 1.5 3.64 3000 1000 1.25 1.20
Siemens Trio 140 3.0 2.94 2300 900 1.00 1.20
Siemens Trio 4 2.9 2.94 2300 900 1.00 1.20
Siemens Trio 44 2.9 2.94 2300 900 1.00 1.20
Siemens Trio 5 3.0 2.94 2300 900 1.00 1.20
Siemens Trio 55 2.9 2.94 2300 900 1.00 1.20
Siemens Trio 6 2.9 2.94 2300 900 1.00 1.20
Siemens Trio 6 2.9 2.94 2300 900 1.00 1.20
Siemens Trio 6 3.0 2.96 2300 900 1.00 1.20
Siemens Trio 9 3.0 2.94 2300 900 1.00 1.20
Siemens Triotim 12 3.0 2.86 - 2.91 2300 900 1.00 - 1.03 1.20
Siemens Triotim 12 3.0 2.91 2300 900 1.00 1.20
Siemens Triotim 13 3.0 2.91 2300 900 1.00 1.20
Siemens Triotim 15 3.0 2.86 - 2.91 2300 900 1.00 1.20
Siemens Triotim 16 3.0 2.91 2300 900 1.00 1.20
Siemens Triotim 2 3.0 2.91 2300 900 1.00 1.20
Siemens Triotim 2 3.0 2.91 2300 900 1.00 1.20
Siemens Triotim 2 3.0 2.91 2300 900 1.00 1.20
Siemens Triotim 22 3.0 2.86 - 2.91 2300 900 1.00 1.20
Siemens Triotim 4 3.0 2.91 2300 900 1.00 1.20
Table A.3: Scanners and scanning parameters of the AddNeuroMed cohort. Abbreviations: Echo time (TE);
Repetition time (TR); Inversion recovery time (IT); Slice thickness (ST); Resolution in x-y-plane (x-y, equal
lengths).
Scanner N FS (T) TE (ms) TR (ms) IT (ms) x-y (mm) ST (mm)
GE Genesis Signa 7 1.5 4.09 10.20 1000 0.94 1.20
GE Signa HDx 4 1.5 4.10 10.20 1000 0.94 1.20
GE Genesis Signa 24 1.5 4.09 10.40 1000 0.94 1.20
GE Genesis Signa 31 1.5 4.09 10.20 1000 0.94 1.20
GE Signa HDx 10 1.5 3.80 8.59-8.60 1000 0.94-1.02 1.20
Siemens Avanto 28 1.5 3.50 2400 1000 1.17 1.20
Picker Edge 1.5T 18 1.5 3.00 13.00 — 0.94 1.20
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Table A.4: Detailed MRI protocols and scanners from the MemClin cohort, where each row represent an individual
scanner. Abbreviations: Echo time (TE); Repetition time (TR); Inversion recovery time (IT); Slice thickness (ST);
Resolution in x-y-plane (x-y, equal lengths).
Scanner N FS (T) TE (ms) TR (ms) IT (ms) x-y (mm) ST (mm)
Siemens Aera 2 1.5 3.18 2300 904 1.25 1.20
Siemens Avanto 204 1.5 2.56 - 4.19 1160 - 2400 600 - 1100 0.45 - 1.30 1.20 - 2.50
Siemens Magnetom vision 36 1.5 4.40 11.40 300 0.90 2.50 - 2.50
Siemens Symphony 85 1.5 3.93 1960 790 - 875 0.49 1.41 - 1.51
Siemens Triotim 57 3.0 2.57 - 3.42 1780 - 2300 900 0.85 - 1 1 - 1.40
Table A.5: Scanners and scanning parameters of the E-DLB cohort. The linespaces in the table are used to
separate between clinics. Abbreviations: Echo time (TE); Repetition time (TR); Inversion recovery time (IT);
Slice thickness (ST); Resolution in x-y-plane (x-y, equal lengths).
Scanner N FS (T) TR (ms) TE (ms) IT (ms) Res. (mm) ST (mm)
Philips Intera Achieva (E-DLBC1) 101 3 8.3 4.6 1250 1.00 1.00
Siemens Verio (E-DLBC2) 165 3 1900 2.53 900 1.00 1.00
BRE Siemens Avanto 24 1.50 2050 2.56 1100 0.50 1.00
GE Discovery MR750 3 3 8.16-9.82 3.18-4.31 450 0.47-1.00 1.00-1.40
Siemens Symphony 9 1.50 1630-1700 3.93 1100 0.48-0.59 1.00-1.17
Philips Achieva 9 3 10.75 5.07 — 0.80 0.80
Philips — 15 — 19.00 3.68-3.75 — 0.80 1.00
GE Signa Excite 6 1.5 22.00 7.00 — 1.02-1.09 1.60
GE Signa HDxt 11 1.5 11.14-11.44 4.98-5.15 — 0.50 1.00
Philips Achieva 10 1.5 25 5.28-5.42 — 0.45 0.80
Philips Achieva 17 1.5 7.07-25 3.21-4.61 — 0.94-1.00 1.00
Siemens TrioTim 5 3 2300 4.68-4.71 1100 1.00 1.00-1.09
GE Signa Excite 41 1.5 8.22 3.12 500-1981 0.50-1.10 1.00-1.10
Philips Intera 1 1.5 20 4.60 — 0.98 1.00
Philips Intera 99 1.5 7.10 3.21 — 1.00 1.00
Siemens Avanto 59 1.5 1820 3.04 1100-2500 0.96-1.00 1.00-1.04
Philips Achieva 13 1.5 8.54 3.988 — 0.94 1.20
Philips Achieva 12 3 13.03-13.15 7.31-7.35 — 0.94 1.00
— 45 1.5 — — — 0.60-0.87 0.90-1.04
Table A.6: Scanner and scanning parameter of the test-retest cohort. Abbreviations: Echo time (TE); Repetition
time (TR); Inversion recovery time (IT); Phase angle (PA); Slice thickness (ST); Resolution in x-y-plane (x-y,
equal lengths).
Scanner N FS (T) TR (ms) TE (ms) IT (ms) FA (◦) Res. (mm) ST (mm)
Siemens Aera 24 1.5 1900 3.02 1100 15 1.0 1.5
Siemens Avanto 24 1.5 1900 3.55 1100 15 1.0 1.5
Siemens Trio 24 3 1900 3.39 900 9 1.0 1.5
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